

Formulating with Self-Emulsifying Cream Bases: Kolliphor[®] CSL

Kolliphor[®] CSL (cetostearyl alcohol, sodium lauryl sulfate, and sodium cetostearyl sulfate) is an emulsifier and structuring agent combination product that is suitable for O/W (oil-in-water) formulations.

Its strategically designed self-emulsifying properties allow it to be **used in conjunction with a large spectrum of emollients** including, but not limited to, Kollicream[®] 3 C (cocoyl caprylocaprate, coco-caprylate/caprate), Kollicream[®] OA (oleyl alcohol), and Kollicream[®] IPM (isopropyl myristate). When used alongside another emulsifier such as Kolliphor[®] CSS (sodium cetostearyl sulfate), Kolliphor[®] CSL's emulsifying properties become amplified to allow this material to efficiently form robust topical semisolids. Kolliphor[®] CSL can be **processed using a wide range of formulating techniques** such as the direct conventional method and liquid crystalline lamellar gel method.



Inspiring Medicines for Better Lives

BASF_Pharma BASF Pharma Solutions www.pharma.basf.com

Kolliphor[®] CSL cream


Phase	Ingredient	Wt/wt%
A	Deionized water	75
В	Xanthan gum	0.1
	Euxyl™ K 712	1.5
С	Kolliphor [®] CSL	6
	Kolliphor [®] CSS	2.4
D	Kollicream [®] IPM	15

Procedure:

- 1. Heat A to 95 °C.
- 2. Premix B and add to A while mixing using an overhead mixer.
- 3. Add C to A/B until combined while mixing at a slow speed.
- 4. Test for homogeneity, ensuring the mixture doesn't separate.
- 5. Once fully combined, remove heat and continue to mix until cooled to room temperature.
- 6. Slowly add D, mixing until uniform on slow speed.

Liquid crystalline formulation

The liquid crystalline lamellar gel network technique can be used to form rich, thick creams with the additional benefit of potentially **improved API delivery**. This processing method includes heating the water phase to a high temperature followed by using the heat of the water phase to melt the room temperature wax and emulsifier. By cooling the formulation to room temperature prior to adding the emollient, this technique allows for the **formation of liquid crystals** in the cream structure via lamellar structures formed by the sulfates' hydrophobic tails which can further aid in API skin penetration.



Liquid crystalline structure under polarized light.

Access to standard quality and regulatory documentation is now more efficient than ever. Retrieve your documents 24/7. Sign-up for RegXcellence[®], your free online Quality & Regulatory Assistant that provides a unified platform for compliance documents, filing assistance and audit information.



Sign-up today at: virtualpharmaassistants.basf.com

Contact us for pricing and additional information: pharma-solutions@basf.com

This document, or any information provided herein does not constitute a legally binding obligation of BASF and has been prepared in good faith and is believed to be accurate as of the date of issuance. Unless expressly agreed otherwise in writing in a supply contract or other written agreement between you and BASF:

- (a) To the fullest extent not prohibited by the applicable laws, BASF EXPRESSLY DISCLAIMS ALL OTHER REPRESENTATIONS, WARRANTIES, CONDITIONS OR GUARANTEES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, BY FACT OR LAW, INCLUDING ANY IMPLIED WARRANTIES, REPRESENTATIONS OR CONDITIONS OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, SATISFACTORY QUALITY, NON-INFRINGEMENT, AND ANY REPRESENTATIONS, WARRANTIES, CONDITIONS OR GUARANTEES, ARISING FROM STATUTE, COURSE OF DEALING OR USAGE OF TRADE and BASF HEREBY EXPRESSLY EXCLUDES AND DISCLAIMS ANY LIABILITY RESULTING FROM OR IN CONNECTION WITH THIS DOCUMENT OR ANY INFORMATION PROVIDED HEREIN, including, without limitation, any liability for any direct, consequential, special, or punitive damages relating to or arising therefrom, except in cases of (i) death or personal injury to the extent caused by BASF's sole negligence, (ii) BASF's willful misconduct, fraud or fraudulent misrepresentation or (iii) any matter in respect of which it would be unlawful for BASF to exclude or restrict liability under the applicable laws;
- (b) Any information provided herein can be changed at BASF's sole discretion anytime and neither this document nor the information provided herein may be relied upon to satisfy from any and all obligations you may have to undertake your own inspections and evaluations;
- (c) BASF rejects any obligation to, and will not, automatically update this document and any information provided herein, unless required by applicable law; and
- (d) The user is responsible for confirming that the user has retrieved the most current version of this document from BASF as appropriate

Inspiring Medicines for Better Lives



BASF_Pharma in BASF Pharma Solutions www.pharma.basf.com